The new drug offering comes from two newly announced partnerships with fertility health companies Famlee Health and Cosette Pharma.
These partnerships will allow customers of the Shark Tank star’s low-cost drug company to access affordable fertility medications from home, which may help patients avoid other costly procedures, according to an Oct. 2 news release.
In addition to Clomid, Cost Plus Drug Co. has plans to add other fertility drugs to its list of available medications in the coming months as well, Mark Cuban confirmed to Becker’s.
“We are working on adding as many drugs related to women’s health and fertility as possible,” Mr. Cuban said.
The move is also a strategic way to disrupt the pink tax that is often placed on items, including drugs, that are marketed to women, he explained.
“We are doing our best to try to find drugs that we can price at our cost plus 15 percent, eliminating the pink tax,” Mr. Cuban said.
The cost plus 15 percent is the company’s business model: a 15 percent markup + $5 shipping + a $5 pharmacy operations fee.
Famlee Health and Cosette Pharma share goals of increasing access to fertility medication, and partnering with Cost Plus will expand their reach.
In a LinkedIn post, Famlee Health stated that the partnership with Cost Plus Drugs, will allow it to continue “to make a positive impact together for women navigating their fertility journey.”
“Access and affordability are top priorities for Cosette, and the partnership with Cost Plus Drugs is an example of our ongoing commitment to patients,” Apurva Saraf, CEO of Cosette Pharma, said in the news release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
